In a patient with dysuria and a urine culture growing 50,000–99,000 CFU/mL Klebsiella species resistant to all tested antibiotics, what is the appropriate treatment regimen?

Treatment of Pan-Resistant Klebsiella UTI

For a patient with dysuria and 50,000-99,000 CFU/mL Klebsiella resistant to all tested antibiotics, you must first determine if this represents true infection versus colonization, then obtain repeat susceptibility testing including newer agents, and empirically treat with ceftazidime-avibactam 2.5 g IV q8h while awaiting results.

Critical First Steps

1. Distinguish Infection from Colonization

• Colony count of 50,000-99,000 CFU/mL is borderline and may represent colonization rather than true infection
• True cystitis requires: dysuria PLUS urinary frequency, urgency, or suprapubic pain
• If only dysuria without classic bladder symptoms, consider alternative diagnoses (vaginitis, urethritis, STI)
• Do not treat asymptomatic bacteriuria - even with resistant organisms, treatment increases resistance without benefit

2. Assess Infection Severity

Requires same-day in-person evaluation if:

• Fever, chills, flank pain, costovertebral angle tenderness (suggests pyelonephritis)
• Severe systemic symptoms, hemodynamic instability
• Concern for urinary obstruction

Simple cystitis symptoms only:

• Dysuria with frequency/urgency/suprapubic pain
• No fever or systemic symptoms
• No recent instrumentation

Antibiotic Selection Strategy

For Carbapenem-Resistant Enterobacterales (CRE) UTI

The 2022 multidrug-resistant organism guidelines provide clear treatment hierarchies 1:

First-Line Options for Complicated UTI:

• Ceftazidime-avibactam 2.5 g IV q8h (5-7 days) 1
• Meropenem-vaborbactam 4 g IV q8h (5-7 days) 1
• Imipenem-cilastatin-relebactam 1.25 g IV q6h (5-7 days) 1

Aminoglycoside Options (if susceptible):

• Gentamicin 5-7 mg/kg/day IV once daily 1
• Amikacin 15 mg/kg/day IV once daily 1
• Plazomicin 15 mg/kg IV q12h 1

For Simple Cystitis (if truly pan-resistant):

• Single-dose aminoglycoside (gentamicin or amikacin) achieves urinary concentrations 25-100 fold above plasma levels and maintains therapeutic levels for days 1
• Microbiologic cure rates of 87-100% for lower UTI 1

Critical Testing Gap

Your "resistance to all tested antibiotics" likely did NOT include:

• Ceftazidime-avibactam
• Meropenem-vaborbactam
• Imipenem-cilastatin-relebactam
• Plazomicin

Immediate action: Request expanded susceptibility testing including these newer β-lactam/β-lactamase inhibitor combinations 1, 2. Most clinical labs do not routinely test these agents.

Treatment Algorithm

If Patient Has Simple Cystitis Symptoms:

1. Confirm true infection (not just dysuria alone)
2. Request expanded susceptibility testing including newer agents
3. If aminoglycoside susceptible: Single-dose gentamicin 5-7 mg/kg IV or amikacin 15 mg/kg IV 1, 3
4. If aminoglycoside resistant: Start ceftazidime-avibactam 2.5 g IV q8h empirically 1
5. Duration: 5-7 days 1

If Patient Has Complicated UTI or Pyelonephritis:

1. Hospitalize for IV therapy
2. Start ceftazidime-avibactam 2.5 g IV q8h (most widely available and preferred by clinicians) 1, 2
3. Alternative: Meropenem-vaborbactam 4 g IV q8h or imipenem-cilastatin-relebactam 1.25 g IV q6h 1
4. Consider combination therapy if critically ill: add aminoglycoside or polymyxin if susceptible 1, 4
5. Duration: 7-14 days for pyelonephritis 1

Special Considerations

Resistance Mechanisms Matter

• KPC-producers: Ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam all effective 1
• MBL-producers (NDM, VIM): Ceftazidime-avibactam + aztreonam combination shows moderate-certainty evidence for efficacy 4
• OXA-48 producers: Ceftazidime-avibactam effective 1

Aminoglycoside Efficacy in CRE UTI

Despite in vitro resistance patterns, aminoglycosides achieve exceptional urinary concentrations. A 2011 study showed 88% microbiologic clearance with aminoglycosides versus 64% with polymyxin B and 43% with tigecycline for carbapenem-resistant Klebsiella bacteriuria 3. This supports single-dose aminoglycoside for simple cystitis even with borderline susceptibility.

Fosfomycin Consideration

While oral fosfomycin is frequently selected by clinicians for uncomplicated CRE cystitis 2, susceptibility to fosfomycin trometamol in carbapenem-resistant Klebsiella is only 33.7% 5. Do not use empirically without documented susceptibility.

Common Pitfalls

1. Treating colonization: 50,000-99,000 CFU/mL with dysuria alone may not be true UTI
2. Assuming "pan-resistant" includes newer agents: Most labs don't test ceftazidime-avibactam, meropenem-vaborbactam, or plazomicin routinely
3. Underestimating aminoglycoside efficacy: Urinary concentrations overcome apparent resistance for lower UTI
4. Using tigecycline for UTI: Achieves inadequate urinary levels; 43% clearance rate versus 88% with aminoglycosides 3
5. Empiric fosfomycin without susceptibility: Only 34% of CRE strains susceptible 5

Infectious Disease Consultation

Mandatory consultation for:

• Confirmed pan-resistant organism after expanded testing
• Critically ill patient
• Recurrent CRE infections
• Need for combination therapy guidance
• MBL-producing strains requiring ceftazidime-avibactam + aztreonam 4